PARIS, Feb 24 (APM) - France's Official Journal (JO) on Tuesday published an order removing, as of March 1, eight drugs from the list of costly drugs reimbursed over and above hospitalisation services.
These removals from the "liste en sus" of costly drugs for use in hospitals, follow on from recommendations made by the ministerial financial advisory board for hospitalisation and concern old drugs.
In 2014, they were all re-evaluated by the Transparency Commission (CT) that lowered their therapeutic value (SMR) and/or their clinical benefit ranking (ASMR).
In the case of several of these drugs, they had come before the CT at a time when it did not attribute clinical benefit rankings to hospital drugs.
The drugs concerned are:
:: Boehringer Ingelheim’s treatment for limb soft tissue sarcomas Beromun (tasonermin) for which the ASMR ranking had not been determined when it was initially added to the liste en sus, and that was estimated to be ASMR V (nil benefit).
:: Novex Pharma’s treatment for Kaposi’s sarcoma DaunoXome (liposomal daunorubicin) for which the ASMR has fallen from III (moderate benefit) to V (nil benefit)
:: Bioprojet’s cytoprotector Ethyol (amifostine) for which the SMR has been judged insufficient
:: GE Healthcare’s palliative treatment for pain linked to bone metastases Metastron (radioactive strontium chloride) for which the SMR, initially not determined, has been judged as low
:: Servier’s melanoma treatment Muphoran (fotemustine) for which the ASMR, initially not determined, has been judged as V (nil benefit)
:: Bioprojet’s treatment for non-small cell lung cancer or oesophageal cancer relapses Photofrin (porfimer sodium) for which the ASMR, initially not determined, has been judged as V (nil benefit)
:: Novartis’ treatment for metastatic kidney cancer Proleukin (aldesleukin) for which the SMR has fallen from important to low and the ASMR has gone from not determined to V (nil benefit)
:: Cis bio international’s analgesic treatment for painful osteoblastic skeletal metastases Quadramet (samarium lexidronam pentasodium) for which the SMR has fallen from important to low and the ASMR has gone from not determined to V (nil benefit)
:: Hospira’s treatment for metastatic progression in colorectal cancer Tomudex (raltitrexed) for which the ASMR has gone from not determined to V (nil benefit)
The order also comprises a restriction in the liste en sus reimbursed indications for Merck Sharp & Dohme’s Caelyx (doxorubicin) as of March 1. The indications that will continue to be reimbursed are:
:: treatment of advanced stage ovarian cancer in women following failure of first line platinum-based chemotherapy
:: in single therapy in patients with metastatic breast cancer, with increased cardiac risk
:: in combination with Johnson & Johnson group-member Janssen’s Velcade (bortezomib) in the treatment of multiple myeloma in progression in patients who have already received at least one previous treatment and who have already undergone or who are not eligible for bone marrow transplant.
This modification in the conditions amounts to no longer reimbursing Caelyx on the liste en sus in the treatment of Kaposi’s sarcoma.
(Journal officiel of February 24, texts 22, 23 & 24)
eh/aki/rs
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
